Peg-grafeel

What is Peg-grafeel?

Peg-grafeel is a long-acting granulocyte colony-stimulating factor (G-CSF) biosimilar of peg-filgrastim. It is designed to enhance neutrophil production, helping the immune system recover after chemotherapy. The pegylation process extends its duration of action, allowing for less frequent dosing compared to filgrastim. Peg-grafeel is primarily used as part of supportive cancer care to reduce the risk of febrile neutropenia and associated infections in patients undergoing chemotherapy.

Storage Conditions

2-8 degrees Celsius (refrigerate), Do not freeze.

Presentation

PFS containing drug.

Route of Administration

Subcutaneous (SC) (upon prescription only and administered by a healthcare provider).

Prevention of Febrile Neutropenia (Hematology):

Febrile neutropenia is a serious medical condition where a fever develops in a person with neutropenia, a condition where there are abnormally low levels of neutrophils, a type of white blood cell crucial for fighting infections. It's a common complication of cancer treatment. Peg-grafeel is indicated for the prevention of febrile neutropenia in patients undergoing myelosuppressive chemotherapy.

Supportive Care in Oncology (Oncology):

Chemotherapy-induced anemia (CIA) is a common side effect of cancer treatment, particularly chemotherapy, where the drugs damage bone marrow cells responsible for red blood cell production, leading to a decrease in the number of red blood cells and the capacity to carry oxygen. Peg-grafeel is part of supportive care in oncology, aimed at preventing chemotherapy-induced neutropenia and its complications.

Prevention of Febrile Neutropenia (Hematology):

Supportive Care in Oncology (Oncology):

Prevention of Febrile Neutropenia (Hematology):

Supportive Care in Oncology (Oncology):

How Peg-filgrastim works?

Mechanism of Action

Peg-grafeel stimulates neutrophil production by binding to G-CSF receptors on hematopoietic cells in the bone marrow. This activates the JAK-STAT pathway, leading to the proliferation, maturation, and release of neutrophils into the bloodstream. The pegylation of filgrastim prolongs its half-life, allowing for sustained action and reducing the need for frequent dosing, making it effective with a single dose per chemotherapy cycle. This helps prevent neutropenia-related infections and supports uninterrupted cancer treatment.